AR057984A1 - DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE - Google Patents

DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE

Info

Publication number
AR057984A1
AR057984A1 ARP060105054A ARP060105054A AR057984A1 AR 057984 A1 AR057984 A1 AR 057984A1 AR P060105054 A ARP060105054 A AR P060105054A AR P060105054 A ARP060105054 A AR P060105054A AR 057984 A1 AR057984 A1 AR 057984A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkynyl
alkenyl
optionally substituted
Prior art date
Application number
ARP060105054A
Other languages
English (en)
Original Assignee
Astex Therapeutics Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38049092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057984(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Therapeutics Ltd, Astrazeneca Ab filed Critical Astex Therapeutics Ltd
Publication of AR057984A1 publication Critical patent/AR057984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/24—Halogenated aromatic hydrocarbons with unsaturated side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1747—Unsaturated ethers containing halogen containing six-membered aromatic rings containing six membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), en la cual R1 está seleccionada entre hidrogeno, alquilo C1-6, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6, cicloalquenilo C5-7, arilo, heteroarilo, heterociclilo, alquil C1-6-cicloalquilo C3-6, alquilarilo C1-6, alquilheteroarilo C1-6 o alquilheterociclilo C1-6, donde el alquilo C1-6, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6, cicloalquenilo C5-7, arilo, heteroarilo, heterociclilo, alquil C1-6-cicloalquilo C3-6, alquilarilo C1-6, alquilheteroarilo C1-6 o alquilheterociclilo C1-6 están opcionalmente sustituidos con uno, dos o tres A; R2 está seleccionado entre hidrogeno, nitro, ciano, -Q-alquilo C1-6, -Q-alquenilo C2-6, -Q-alquinilo C2-6, -Q-cicloalquilo C3-6, -Q- cicloalquenilo C5-7, -Q-alquil C1-6cicloalquilo C3-6, -Q-arilo, -Q-heteroarilo, -Q-alquilarilo C1-6, -Q-alquilheteroarilo C1-6, -Q-heterociclilo, o -Q- alquilheterociclilo C1-6, donde dicho -Q-alquilo C1-6, -Q-alquenilo C2-6, -O-alquinilo C2-6, -Q- cicloalquilo C3-6, -Q-cicloalquenilo C5-7, -Q-alquil C1-6-cicloalquilo C3-6, -Q-arilo, -Q-heteroarilo, -Q-alquilarilo C1-6, -Q-alquiIheteroarilo C1-6, -Q-heterociclilo, o -Q-alquilheterociclilo C1-6 están opcionalmente sustituidos con uno, dos o tres R7; -Q- es un enlace directo, -CONH-, -CO-, -CON(alquilo C1-6)-, -CON(cicloalquilo C3-6)-, -SO-, -SO2-, -SO2NH-, -SO2N(alquilo C1-6)-, -SO2N(cicloalquilo C3-6)-, -NHSO2-, -N(alquilo C1-6)SO2-, -NHCO-, -N(alquilo C1-6)CO-, -N(cicloalquilo C3- 6)CO- o -N(cicloalquil C3-6)SO2-; R3 es (C(R4)(R5))nR6, alquenilo C2-4R6, alquinilo C2-4R6, cicloalquenilo C5-7R6, nitro o ciano y si n > 1 entonces cada C(R4)(R5) es independiente de los otros; R4 y R5 están independientemente seleccionados de hidrogeno, alquilo C1-6, ciano, halo o nitro; o R4 y R5 conjuntamente forman oxo, cicloalquilo C3-6 o heterociclilo; R6 está seleccionado de metilo, cicloalquilo C3-6, heterociclilo, arilo o heteroarilo donde cada uno de dichos metilo, cicloalquilo C3-6, heterociclilo, arilo o heteroarilo está opcionalmente sustituido con entre uno y cuatro R7, y donde cualquiera de los grupos arilo o heteroarilo individuales puede estar opcionalmente fusionado con un grupo cicloalquilo, cicloalquenilo o heterociclilo de 4, 5, 6 o 7 miembros para formar un sistema de anillos bicíclico donde el sistema de anillo bicíclico está opcionalmente sustituido con entre uno y cuatro A con la condicion de que el anillo bicíclico no sea un sistema de anillo indano, benzo[1,3]dioxol o 2,3-dihidrobenzo[1,4]-dioxina; R7 está seleccionado de halogeno, nitro, CHO, alquilo C0-6CN, O-alquilo C1-6CN, alquilo C0-6OR8, O-alquilo C2-6OR8, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, alquilo C0-6NR8R9, O-alquilo C2-6NR8R9, O-alquilo C2-6-O-alquilo C2-6NR8R9, NR8OR9, alquilo C0-6CO2R8, O-alquilo C1-6CO2R8, alquilo C0-6CONR8R9, O-alquilo C1-6CONR8R9, O-alquilo C2-6NR8(CO)R9, alquilo C0-6NR8(CO)R9, O(CO)NR8R9, NR8(CO)OR9, NR8(CO)NR8R9, O(CO)OR8, O(CO)R8, alquilo C0-6COR8, O-alquilo C1-6COR8, NR8(CO)(CO)R8, NR8(CO)(CO)NR8R9, alquilo C0-6SR8, alquilo C0-6(SO2)NR8R9, O-alquilo C1-6NR8(SO2)R9, O-alquilo C0-6(SO2)NR8R9, alquilo C0-6(SO)NR8R9, O- alquilo C1-6(SO)NR8R9, OSO2R8, SO3R8, alquilo C0-6NR8(SO2)NR8R9, alquilo C0-6NR8(SO)R9, O-alquilo C2-6NR8(SO)R8, O-alquilo C1-6SO2R8, alquilo C1-6SO2R8, alquilo C0-6SOR8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquil C0-6cicloalquilo C3-6, alquilarilo C0-6, alquilheteroariIo C0-6, alquilheterociclilo C0-6, y O-alquilheterociclilo C2-6, donde cualquier alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilo C0-6cicloalquilo C3-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilheterocicliIo C0-6, y O-alquilheterociclilo C2-6 puede estar opcionalmente sustituido con uno o más R14, y donde cualquiera de los grupos arilo y heteroarilo individuales pueden estar opcionalmente fusionados con un grupo cicloalquilo, cicloalquenilo o heterociclilo de 4, 5, 6 o 7 miembros, para formar un sistema de anillo bicíclico donde el sistema de anillo bicíclico está opcionalmente sustituido con entre uno y cuatro A con la condicion de dicho sistema de anillo bicíclico no sea un sistema de anillo indano, benzo[1,3]dioxol o 2,3-dihidrobenzo[1,4]-dioxina; R14 está seleccionado entre halogeno, nitro, CHO, alquilo C0-6CN, O-alquilo C1-6CN, alquilo C0-6OR8, O-alquilo C1-6OR8, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, alquilo C0-6NR8R9, O-alquilo C2-6NR8R9, O-alquilo C2-6O-alquilo C2-6NR8R9, NR8OR9, alquilo C0-6CO2R8, O-alquilo C1-6CO2R8, alquilo C0-6CONR8R9, O-alquilo C1-6CONR8R9, O-alquilo C2-6NR8(CO)R9, alquilo C0- 6NR8(CO)R9, O(CO)NR8R9, NR8(CO)OR9, NR8(CO)NR8R9, OR8, O(CO)OR8, O(CO)R8, alquilo C0-6COR8, O-alquilo C1-6COR8, NR8(CO)(CO)R8, NR8(CO)(CO)NR8R9, alquilo C0-6SR8, alquilo C0-6(SO2)NR8R9, O-alquilo C2-6NR8(SO2)R9, O-alquilo C0-6(SO2)NR8R9, alquilo C0- 6(SO)N R8R9, O-alquilo C1-6(SO)NR8R9, OSO2R8, OSO2R8R9, SO3R8, alquilo C0-6NR8(SO2)NR8R9, alquilo C0-6NR8(SO)R9, O-alquilo C2-6NR8(SO)R9, O-alquilo C1-6SO2R8, alquilo C1-6SO2R8, alquilo C0-6SOR8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilo C0-6-cicloalquilo C3-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilheterociclilo C0-6 y O-alquilheterociclilo C2-6; donde cualquier alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilo C0-6-cicloalquilo C3-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilheterociclilo C0-6 y Oalquilheterociclilo C2-6 pueden estar opcionalmente sustituidos con entre uno y cuatro A; R8 y R9 están independientemente seleccionados entre hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2- 6, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, alquilo C0-6-cicloalquilo C3-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquiIheterocicIilo C0-6 y alquilo C0-6NR10R11, donde el alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilo C0-6cicloalquilo C3-6, alquilarilo C0-6, alquilheteroariio C0-6 o alquilheterociclilo C0-6 están opcionalmente sustituidos con A; o R8 y R9 pueden formar conjuntamente un anillo heterocíclico de 4 a 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S que está opcionalmente sustituido con A; siempre que dos grupos R8 ocurren en la estructura entonces estos pueden formar opcionalmente, conjuntamente un anillo heterocíclico de 5 o 6 que contiene uno o más heteroátomos seleccionados entre N, O o S, que está opcionalmente sustituido con A; R10 y R11 están independientemente seleccionados de hidrogeno, alquilo C1-6, alquenilo C3-6, alquinilo C3-6, alquil C0-6-cicloalquilo C3-6, alquilarilo C0-6, alquilheterociclilo C0-6 y alquilheteroarilo C0-6, donde el alquilo C1-6, alquenilo C3-6, alquinilo C3-6, alquilo C0-6cicloalquilo C3-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilheterociclilo C0-6 están opcionalmente sustituidos con A; o R10 y R11 pueden formar conjuntamente un anillo heterocíclico de 4 a 6 miembros que contienen uno o más heteroátomos seleccionados entre N, O o S opcionalmente sustituidos con A; n es 0, 1, 2 o 3; A está seleccionada entre oxo, halogeno, nitro, CN, OR12, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilo C0-6cicloalquilo C3-6, alquilheterociclilo C0-6, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, O-alquilo C2-6NR12R13, NR12R13, CONR12R13, NR12(CO)R13, O(CO)alquilo C1-6, (CO)O-alquilo C1-6, COR12, (SO2)NR12R13, NSO2R12, SO2R12, SOR12, (CO)alquilo C1-6NR12R13, (SO2)alquilo C1-6NR12R13, OSO2R12, SO3R12 donde los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilarilo C0-6, alquilheteroarilo C0-6, alquilheterociclilo C0-6 y alquilo C0-6cicloalquilo C3-6 pueden estar opcionalmente sustituidos con halo, OSO2R12, SO3R12, nitro, ciano, OR12, alquilo C1-6, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi y trifluorometoxi; R12 y R13 están independientemente seleccionados entre hidrogeno, alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo o heterociclilo donde dicho alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno, dos o tres hidroxi, ciano, halo o alquiloxiC1-3; o R12 y R13 pueden formar conjuntamente un anillo heterocíclico de 4 a 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S opcionalmente sustituidos con hidroxi, alquiloxi C1-3, ciano o halo; con la condicion de que cualquiera de los grupos arilo o heteroarilo en R1, R2 o R3 está sustituido con un grupo OSO2R8, SO3R8, OSO2R12 o SO3R12; o con la condicion de cualquiera de los grupos arilo o heteroarilo individuales en R1, R2 o R3 están fusionados con un grupo cicloalquilo, cicloalquenilo o heterociclilo de 4, 5, 6 o 7 miembros para formar un sistema de anillo bicíclico donde el sistema de anillo bicíclico está opcionalmente sustituido con entre uno y cuatro A con la condicion de que el anillo bicíclico no sea un sistema de anillo indano, benzo[1,3jdioxol o 2,3- dihidrobenzo[1,4]-dioxina; o con la condicion de que R1 sea alquinilo C3-6 o cicloalquenilo C5-7 opcionalmente sustituido con uno, dos o tres A; o con la condicion de que Q esté seleccionado entre -NHSO2-, -N(alquilo C1-6)SO2-, -SO2NH-, -SO2N(alquilo C1-6)- o -SO2N(cicloalquilo C3-6)- , -SO-, -SO2- o -N(cicloalquilo C3-6)SO2-; o con la condicion de que R3 esté seleccionado entre alquenilo C2-4R6, alquinilo C2-4R6, cicloalquenilo C5-7R6, nitro o ciano; o con la condicion de que R2 esté seleccionado de un grupo que consiste en nitro, ciano, alquinillo C2-6, cicloalquenilo C5-7 o alquenilo C2-6 donde el grupo alquinilo C2-6, cicloalquenilo C5-7 o alquenilo C2-6 esté opcionalmente sustituido con uno, dos o tres R7; en forma de una base libre o una sal, solvato o solvato de una sal de éste farmacéuticamente aceptable.
ARP060105054A 2005-11-21 2006-11-17 DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE AR057984A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73865005P 2005-11-21 2005-11-21
US81574606P 2006-06-22 2006-06-22

Publications (1)

Publication Number Publication Date
AR057984A1 true AR057984A1 (es) 2008-01-09

Family

ID=38049092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105054A AR057984A1 (es) 2005-11-21 2006-11-17 DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE

Country Status (14)

Country Link
US (1) US20090233930A9 (es)
EP (1) EP1979324A4 (es)
JP (1) JP2009519221A (es)
KR (1) KR20080080565A (es)
AR (1) AR057984A1 (es)
AU (1) AU2006316049A1 (es)
BR (1) BRPI0618845A2 (es)
CA (1) CA2630680A1 (es)
EC (1) ECSP088499A (es)
NO (1) NO20082673L (es)
RU (1) RU2008121756A (es)
TW (1) TW200734311A (es)
UY (1) UY29927A1 (es)
WO (1) WO2007058602A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
CN101360716A (zh) * 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200831091A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076043A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902503A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
KR101259240B1 (ko) * 2008-02-18 2013-04-29 시에나 바이오테크 에스.피.에이. 4,5-다이하이드로-옥사졸-2-일 아민 유도체
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
JP5381257B2 (ja) * 2009-04-09 2014-01-08 ユニマテック株式会社 含フッ素ボロン酸エステル化合物の製造方法
UY32750A (es) * 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
TW201105650A (en) * 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
CN102030770B (zh) * 2009-09-25 2012-10-31 北京大学 一种芳香硼酸酯化合物的制备方法
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
EP2368884A1 (en) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Process for the preparation of bosentan
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
JP5853617B2 (ja) * 2011-11-11 2016-02-09 Dic株式会社 アゾベンゼン誘導体及びこれを含有する液晶組成物
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9353089B2 (en) 2013-03-26 2016-05-31 Saint Louis University Compositions and methods for the treatment of malaria
ES2640482T3 (es) 2013-04-16 2017-11-03 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG163508A1 (en) * 2003-12-15 2010-08-30 Schering Corp Heterocyclic aspartyl protease inhibitors
ATE444962T1 (de) * 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
US7759353B2 (en) * 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
CA2609562A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
JP2009500329A (ja) * 2005-06-30 2009-01-08 ワイス アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
ATE478070T1 (de) * 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
EP1943246A1 (en) * 2005-10-31 2008-07-16 Schering Corporation Aspartyl protease inhibitors

Also Published As

Publication number Publication date
BRPI0618845A2 (pt) 2016-09-13
WO2007058602A3 (en) 2007-07-05
EP1979324A2 (en) 2008-10-15
CA2630680A1 (en) 2007-05-24
RU2008121756A (ru) 2009-12-27
WO2007058602A2 (en) 2007-05-24
NO20082673L (no) 2008-07-23
JP2009519221A (ja) 2009-05-14
KR20080080565A (ko) 2008-09-04
ECSP088499A (es) 2008-07-30
UY29927A1 (es) 2007-06-29
US20080293718A1 (en) 2008-11-27
AU2006316049A1 (en) 2007-05-24
TW200734311A (en) 2007-09-16
EP1979324A4 (en) 2011-11-09
US20090233930A9 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
AR057984A1 (es) DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR058381A1 (es) Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR061370A1 (es) Derivados de imidazopirimidina
AR061372A1 (es) Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR059687A1 (es) Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion.
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR048523A1 (es) Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR047744A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico
AR060605A1 (es) Derivados de diazepano como antagonistas del receptor ccr2
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR055878A1 (es) Derivados de ciclopropanocarboxamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal